JOHN HOPE FRANKLIN CENTER

JOHN HOPE FRANKLIN CENTER logo
🇺🇸United States
Ownership
Private
Established
1838-01-01
Employees
5K
Market Cap
-
Website
http://www.duke.edu
Clinical Trials
Related News

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

First Posted Date
2004-07-29
Last Posted Date
2013-02-20
Lead Sponsor
Duke University
Target Recruit Count
6
Registration Number
NCT00002754
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-07-29
Last Posted Date
2013-02-18
Lead Sponsor
Duke University
Target Recruit Count
6
Registration Number
NCT00002753
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Monoclonal Antibody Therapy in Treating Patients With Brain Metastases

Phase 1
Completed
Conditions
Metastatic Cancer
First Posted Date
2004-07-01
Last Posted Date
2013-06-20
Lead Sponsor
Duke University
Target Recruit Count
6
Registration Number
NCT00002751
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Phase 1
Withdrawn
Conditions
Leukemia
Lymphoma
First Posted Date
2004-06-09
Last Posted Date
2013-03-07
Lead Sponsor
Duke University
Registration Number
NCT00003435
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Melphalan in Patients With Neoplastic Meningitis

First Posted Date
2004-05-24
Last Posted Date
2013-02-20
Lead Sponsor
Duke University
Target Recruit Count
6
Registration Number
NCT00002750
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
First Posted Date
2004-05-20
Last Posted Date
2013-03-21
Lead Sponsor
Duke University
Target Recruit Count
17
Registration Number
NCT00004211
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-19
Last Posted Date
2013-02-20
Lead Sponsor
Duke University
Target Recruit Count
24
Registration Number
NCT00003020
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

🇺🇸

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-19
Last Posted Date
2013-06-20
Lead Sponsor
Duke University
Target Recruit Count
36
Registration Number
NCT00002988
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

First Posted Date
2004-05-04
Last Posted Date
2015-10-15
Lead Sponsor
Duke University
Target Recruit Count
19
Registration Number
NCT00006342
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-03
Last Posted Date
2014-08-21
Lead Sponsor
Duke University
Registration Number
NCT00005081
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy